Literature DB >> 19696126

Patient-reported dyspnea in COPD reliability and association with stage of disease.

Donald A Mahler1, Joseph Ward2, Laurie A Waterman2, Corliss McCusker3, Richard ZuWallack3, John C Baird4.   

Abstract

BACKGROUND: Although questionnaires are used frequently with patients to self-report the severity of dyspnea as related to activities of daily living, the reliability of these instruments has not been established. The two purposes of this study were to examine the test-retest reliability of three widely used dyspnea instruments and to compare dyspnea scores at different stages of disease.
METHODS: At paired baseline visits, 101 stable patients with COPD were tested; at paired follow-up visits at 3 months, 89 of these patients were tested. At each visit, patients rated dyspnea with three instruments presented in random order and then performed post-bronchodilator therapy lung function tests.
RESULTS: Patient-reported dyspnea scores and lung function were similar at baseline (interval, 6 +/- 5 days) and follow-up visits (interval, 4 +/- 2 days). Intraclass correlation coefficients at baseline and at follow-up were 0.82 and 0.82, respectively, for the modified Medical Research Council scale; 0.90 and 0.84, respectively, for the self-administered computerized versions of the baseline dyspnea index and transition dyspnea indexes; and 0.95 and 0.89 for the University of San Diego Shortness of Breath Questionnaire results. Dyspnea ratings were significantly related to the stage of disease severity based on percent predicted FEV(1) (p < 0.001).
CONCLUSIONS: Test-retest reliability was acceptable for patient-reported dyspnea scores using three clinical instruments at baseline and at the 3-month follow-up. Our results demonstrate for the first time that patient-reported dyspnea ratings are related to the stage of disease severity.

Entities:  

Mesh:

Year:  2009        PMID: 19696126      PMCID: PMC3026583          DOI: 10.1378/chest.09-0934

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  29 in total

1.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.

Authors:  B R Celli; W MacNee
Journal:  Eur Respir J       Date:  2004-06       Impact factor: 16.671

2.  Development of self-administered versions of modified baseline and transition dyspnea indexes in COPD.

Authors:  Donald A Mahler; Joseph Ward; Gustavo Fierro-Carrion; Laurie A Waterman; Timothy F Lentine; Roberto Mejia-Alfaro; John C Baird
Journal:  COPD       Date:  2004       Impact factor: 2.409

Review 3.  Measurement of breathlessness in advanced disease: a systematic review.

Authors:  C Bausewein; M Farquhar; S Booth; M Gysels; I J Higginson
Journal:  Respir Med       Date:  2006-08-17       Impact factor: 3.415

4.  Reliability and validity of dyspnea measures in patients with obstructive lung disease.

Authors:  E G Eakin; D E Sassi-Dambron; A L Ries; R M Kaplan
Journal:  Int J Behav Med       Date:  1995

5.  Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.

Authors:  Peter Kardos; Marion Wencker; Thomas Glaab; Claus Vogelmeier
Journal:  Am J Respir Crit Care Med       Date:  2006-10-19       Impact factor: 21.405

6.  Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease.

Authors:  J C Bestall; E A Paul; R Garrod; R Garnham; P W Jones; J A Wedzicha
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

7.  Lung volumes in healthy nonsmoking adults.

Authors:  R O Crapo; A H Morris; P D Clayton; C R Nixon
Journal:  Bull Eur Physiopathol Respir       Date:  1982 May-Jun

Review 8.  Pulmonary biomarkers in chronic obstructive pulmonary disease.

Authors:  Peter J Barnes; Badrul Chowdhury; Sergei A Kharitonov; Helgo Magnussen; Clive P Page; Dirkje Postma; Marina Saetta
Journal:  Am J Respir Crit Care Med       Date:  2006-03-23       Impact factor: 21.405

9.  BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Jürgen Behr; Kevin K Brown; Roland M du Bois; Lisa Lancaster; Joao A de Andrade; Gerd Stähler; Isabelle Leconte; Sébastien Roux; Ganesh Raghu
Journal:  Am J Respir Crit Care Med       Date:  2007-09-27       Impact factor: 21.405

10.  Replacement of the 6-min walk test with maximal oxygen consumption in the BODE Index applied to patients with COPD: an equivalency study.

Authors:  Fábio Cardoso; Andréa Thomazine Tufanin; Marcelo Colucci; Oliver Nascimento; José Roberto Jardim
Journal:  Chest       Date:  2007-05-15       Impact factor: 9.410

View more
  31 in total

1.  Patterns of Emphysema Heterogeneity.

Authors:  Arschang Valipour; Pallav L Shah; Wolfgang Gesierich; Ralf Eberhardt; Greg Snell; Charlie Strange; Robert Barry; Avina Gupta; Erik Henne; Sourish Bandyopadhyay; Philippe Raffy; Youbing Yin; Juerg Tschirren; Felix J F Herth
Journal:  Respiration       Date:  2015-10-03       Impact factor: 3.580

2.  GOLD 2011 disease severity classification in COPDGene: a prospective cohort study.

Authors:  MeiLan K Han; Hana Muellerova; Douglas Curran-Everett; Mark T Dransfield; George R Washko; Elizabeth A Regan; Russell P Bowler; Terri H Beaty; John E Hokanson; David A Lynch; Paul W Jones; Antonio Anzueto; Fernando J Martinez; James D Crapo; Edwin K Silverman; Barry J Make
Journal:  Lancet Respir Med       Date:  2012-09-03       Impact factor: 30.700

3.  Risk adjustment for health care financing in chronic disease: what are we missing by failing to account for disease severity?

Authors:  Theodore A Omachi; Steven E Gregorich; Mark D Eisner; Renee A Penaloza; Irina V Tolstykh; Edward H Yelin; Carlos Iribarren; R Adams Dudley; Paul D Blanc
Journal:  Med Care       Date:  2013-08       Impact factor: 2.983

4.  The Role of Inhalation Delivery Devices in COPD: Perspectives of Patients and Health Care Providers.

Authors:  Nicola A Hanania; Sidney Braman; Sandra G Adams; Ruth Adewuya; Arzu Ari; JoAnn Brooks; Donald A Mahler; Jill A Ohar; Jay Peters; Shahin Sanjar
Journal:  Chronic Obstr Pulm Dis       Date:  2018-04-01

Review 5.  The importance of the assessment of pulmonary function in COPD.

Authors:  Kristina L Bailey
Journal:  Med Clin North Am       Date:  2012-05-31       Impact factor: 5.456

6.  Profile of Cardiovascular Disease Patients Who are Diagnosed with COPD in a Smoking-Cessation Unit.

Authors:  Juan A Riesco; María Hidalgo; David Chipayo; José J Gómez; Fernando Zaragozá
Journal:  Adv Ther       Date:  2020-06-13       Impact factor: 3.845

Review 7.  Improving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterol.

Authors:  Gregory J Feldman
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-02-14

8.  Power estimation of tests in log-linear non-uniform association models for ordinal agreement.

Authors:  Fabien Valet; Jean-Yves Mary
Journal:  BMC Med Res Methodol       Date:  2011-05-17       Impact factor: 4.615

9.  Modified Medical Research Council scale vs Baseline Dyspnea Index to evaluate dyspnea in chronic obstructive pulmonary disease.

Authors:  Thierry Perez; Pierre Régis Burgel; Jean-Louis Paillasseur; Denis Caillaud; Gaetan Deslée; Pascal Chanez; Nicolas Roche
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-08-18

Review 10.  Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life.

Authors:  Andrea Rossi; Erika Zanardi; Venerino Poletti; Mario Cazzola
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.